Climb Bio (CLYM) Stock Forecast: StockMap's 2-Week Call

CLYM stock forecast: StockMap's model makes no two-week call on Climb Bio after the Nov 19 close: its evidence is split, 6 reasons for and 9 against. Too few two-week windows graded to judge yet.

Climb Bio last closed at $9.28, -0.22% on the session.

Against the IVW growth benchmark the position is +2.11% over the forecast window.

Climb Bio's market cap is $545.06M as of November 19, 2026.

No call today: the model sees no clear direction · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -13 (too close to call).

Where CLYM sits: sized by market cap, coloured by the day's move.

The read is built from 15 underlying insights — 6 bullish and 9 bearish.

Agreement across those insights is 60%.

6 daily calls for CLYM so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Climb Bio in the 23rd percentile on return on equity, where 100 is best.

Climb Bio is classified under Health Care / Biotechnology.

StockMap tracks Climb Bio as the 166th largest of the 394 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 200 Moderate Underperform, 134 Neutral, 43 Strong Underperform and 17 Moderate Outperform.

On that composite Climb Bio ranks 115th of 394 in the group, against a group median of -0.27.

Other Health Care stocks

Research and education, not investment advice. The calls on this page come from StockMap's automated model, run on the close of November 19, 2026, and are the same for every reader. Calls are graded in public, misses included: how calls are graded, and the record. Who makes the calls and who pays for the site: Disclosures.

Climb Bio (CLYM) — StockMap 2-week forecast & tracked accuracy